Apellis制药 APLS 深 沪
等待开盘 05-12 09:30:00 美东时间
41.025
+0.010
+0.02%
华盛通- 最 高41.14
- 今 开41.04
- 成交量 357.18万股
- 最 低 40.95
- 昨 收 41.015
- 总市值 438.97万
- 52周最高 41.14
- 市盈率 静 --
- 换手率 3338.13%
- 52周最低 16.61
- 委 比 12.01%
- 总股本 0.00亿
- 历史最高 94.75
- 量 比 2.01
- 振 幅 0.46%
- 历史最低 1.10
- 每 手 1
- 风险率 6.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
FDA extends review for Biogen's Leqembi Iqlik for early Alzheimer's disease to August 2026.
05-08 23:31
Remitly Global Set To Join S&P SmallCap 600 Will Replace Apellis Pharmaceuticals
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260507-1483310/1483310_tph-apls-6.pdf
05-08 05:19
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward
Biogen partners with Alloy Therapeutics to advance antisense therapies using RNA-targeting technology, expanding its pipeline.
04-07 20:54
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.
04-06 18:40
Raymond James Downgrades Apellis Pharmaceuticals to Market Perform
Raymond James analyst Ryan Deschner downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Outperform to Market Perform.
04-01 22:21
Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook
US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.2%, while utilities fall 0.7%. FactSet reports upbeat Q2 results and raises outlook.
04-01 00:07
Dow Jumps 400 Points; TD Synnex Posts Upbeat Earnings
US stocks higher, Dow up 0.90%, Nasdaq up 1.61%. Communication services gained 1.8%, utilities fell 0.6%. TD Synnex beats earnings estimates.
03-31 21:42
Apellis Valuation Ignores Empaveli Potential, Says Analyst
BofA upgraded Apellis to Buy, citing strong early Empaveli uptake, FDA approval in rare kidney disease, and long-term sales upside.
01-22 02:14
Apellis Pharmaceuticals FY25 Preliminary U.S. Net Product Revenues Of $689M
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H
01-12 20:10
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
2025-11-13 02:36
